Fennec Pharmaceuticals Inc. Stock Toronto S.E.
Equities
FRX
CA31447P1009
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.1 CAD | -0.55% | +12.62% | -39.97% |
Sales 2024 * | 62.94M 86.05M | Sales 2025 * | 67.21M 91.89M | Capitalization | 182M 248M |
---|---|---|---|---|---|
Net income 2024 * | 14M 19.14M | Net income 2025 * | 16M 21.88M | EV / Sales 2024 * | 2.89 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.7 x |
P/E ratio 2024 * |
13.1
x | P/E ratio 2025 * |
11.3
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.15% |
Latest transcript on Fennec Pharmaceuticals Inc.
1 day | -0.55% | ||
1 week | +12.62% | ||
Current month | +8.08% | ||
1 month | -2.57% | ||
3 months | -33.91% | ||
6 months | -36.01% | ||
Current year | -39.97% |
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 09-07-06 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Mark Gowland
AUD | Comptroller/Controller/Auditor | 52 | 15-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 11-08-24 |
Khalid Islam
CHM | Chairman | 67 | 14-04-24 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-07-17 | 9.1 | -0.55% | 1,202 |
24-07-16 | 9.15 | +0.99% | 600 |
24-07-15 | 9.06 | +4.02% | 8,050 |
24-07-12 | 8.71 | -2.13% | 600 |
24-07-11 | 8.9 | +10.15% | 4,701 |
Delayed Quote Toronto S.E., July 17, 2024 at 03:59 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.03% | 126B | |
+23.61% | 117B | |
+22.77% | 27.52B | |
-18.07% | 20.87B | |
-14.29% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |
- Stock Market
- Equities
- FENC Stock
- FRX Stock